Search

Lidaprim, a new bactericidal combination of trimethoprim and sulfametrol, was administered to 20 patients of a paediatric surgical ward over a period of 7 or more days. Analytic determination of plasma and urine concentrations of the chemotherapeutic agent showed homogeneous drug levels at the chosen dosage. No cumulation was observed. Drug tolerance was excellent. Only one patient developed urticaria when the substance was given together with penicillin, but it was not necessary to stop medication in this case.

Lidaprim, a bactericidal chemotherapeutical agent, was administered to 10 patients in a children's hospital, in the form of an oval suspension for children. The initial dosage was given on an empty stomach, the second after a standard meal. The concentrations of the chemotherapeutical agents in the plasma and the urine were chemically analysed. The bio-availability of the preparation was very good. A standard meal, taken just before dosage, led to a delay in absorption both for Trimethoprim and Sulfametrol. In the period under surveillance, 0-12 hours after administration, an absorption loss could be calculated from the plasma and urine levels in the case of both Trimethoprim and Sulfametrol. In spite of this effect, adequate plasma and urine levels with a bactericidal action, were achieved with the usual dosage. The clinical success and compatibility of the preparation were good in every single case.

Pharmacokinetic parameters were determined after the oral administration of a single tablet containing 200 mg celiprolol HCl to 8 healthy volunteers with normal kidney function and 6 patients with stable impaired renal function of different degrees of severity. The plasma levels and the urinary excretion of celiprolol were followed up for 48 hours after administration with the help of specific chemo-analytical methods. The substance was equally well absorbed both by healthy volunteers and patients with renal disease. While the cumulative renal excretion (0 to 48 hours after administration) was reduced from 18.2% in healthy volunteers to 2.3% of the applied dose in kidney patients, the global elimination constant k fell from 0.104 h-1 in healthy volunteers to 0.072 h-1 in the patients with renal disease. It can be assumed that in patients with impaired renal function at least a part of the lacking renal elimination of celiprolol can be taken over by "extrarenal elimination". According to the method of Dettli a reduction in dosage of the beta 1-blocker, celiprolol is not necessary in patients with more or less impaired kidney function.

A report is given on the examination of the levels of sulfametrole and trimethoprim in blood and lung tissue of 29 patients with pulmonary tumours of various origin, who were subjected to a pre-operative treatment with 2 tablets 2 times daily of the sulfametrole-trimethoprim combination Lidaprim for an average period of one week because of concurrent bronchopulmonary infections. About 14 hours after the last tablet dose samples of tumour-free lung tissue and blood were removed during the operation and subjected to a chemical analysis of sulfametrole and trimethoprim. The mean blood level of sulfametrole was 30.3 micrograms/ml and of trimethoprim 2.0 micrograms/ml; the mean levels in the lung tissue was 19.2 micrograms/g of sulfametrole and 9.2 micrograms/g of trimethoprim. Trimethoprim via the blood is stored in the lung tissue. The relationship of these results to the good clinical activity of the combination sulfametrole/trimethoprim in the treatment of infections of bacterial origin in the upper and lower airways is discussed.